Dexo (Ursodeoxycholic Acid/UDCA) is commonly used as a specialized therapeutic agent that supports the management of conditions related to bile composition and bile flow. The main uses are considered relevant across several key therapeutic areas.

The medication plays a role in managing Primary Biliary Cholangitis (PBC), a chronic autoimmune condition, and is applied in addressing certain types of gallstones. Furthermore, it is relevant for managing symptoms associated with the formation of gallstones in high-risk scenarios, such as patients undergoing rapid weight loss. This provides supportive relief that helps maintain a sense of stability when symptoms are more noticeable.

The therapeutic application is relevant for easing symptoms that create noticeable physiological strain, particularly intense, generalized itching (pruritus), which often interferes with daily functioning. It helps address these symptoms and plays a role in managing conditions presenting with systemic or localized discomfort. This contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Supports Management of Cholestatic Pruritus

Eligibility Map: Who Can and Cannot Use Dexo — Official Regulatory Information

This section details the official rules for the use of Dexo (Ursodeoxycholic Acid/UDCA) as defined in government-approved regulatory documents.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults with Primary Biliary Cholangitis (PBC) and adults for the dissolution of radiolucent, noncalcified gallstones. Use is established for children aged 6 years and older for certain hepatobiliary disorders.
Populations for whom use is not recommended	Pregnant women: The drug is not recommended for use in the first trimester. Women of child-bearing potential must use effective non-hormonal contraception.
Populations for whom use is contraindicated	Individuals with known hypersensitivity to bile acids or the formulation. Patients with a complete obstruction of the biliary tract or acute inflammation of the gallbladder or bile ducts (acute cholecystitis, cholangitis). Patients with calcified (radiopaque) gallstones.
Age-related eligibility rules	Pediatric (Under 6 years): Safety and effectiveness for gallstone dissolution are not established. Infants/Children with Biliary Atresia are contraindicated if good bile flow has not been restored after surgery.
Condition-specific eligibility rules	Use is restricted/conditional in patients with advanced, decompensated hepatic cirrhosis. Use is restricted if the gallbladder has impaired contractility.

---

Eligibility Classifications (High-Level)

Category	Regulatory Status or Classification
Eligibility severity classification	Absolute Contraindications: Biliary obstruction, acute inflammation, calcified stones. Not Recommended: Pregnancy.
Eligibility-context constraints	Dependent on the patency of the biliary tract, the composition of gallstones (must be noncalcified), and the patient's reproductive status.

---

Resulting Eligibility Structure

Official documents define eligibility by focusing on the functional integrity of the hepatobiliary system, classifying individuals with physical obstructions or acute biliary inflammation as absolutely contraindicated. Eligibility is further segmented by age, restricting use in young children where data is not established, and by reproductive status, where use during pregnancy is formally not recommended. Only patients with radiolucent (noncalcified) stones and a functioning biliary tract are generally eligible for gallstone treatment.

The interaction profile of Dexo (Ursodeoxycholic Acid) is defined by documented interferences with its absorption and its effect on the clearance of co-administered medicines.

Timing-Based Separation Requirements

Co-administration with agents that bind bile acids in the gastrointestinal tract is formally documented to reduce the absorption of Ursodeoxycholic Acid, which diminishes its effectiveness. Regulatory labels mandate a separation window for these substances:

• Bile Acid Sequestrants: Medicines such as colestyramine and colestipol must be administered at least two hours before or two hours after the administration of Dexo.
• Aluminum-Containing Antacids: Antacids containing aluminum hydroxide or aluminum oxide are also documented to bind UDCA and require a two-hour time separation from Dexo administration.

Documented Pharmacokinetic Alterations

Ursodeoxycholic Acid has a formal interaction pattern with certain medicines related to clearance pathways:

• Ciclosporin (Cyclosporine): UDCA is documented to increase the plasma concentration of ciclosporin. This elevation in systemic exposure necessitates monitoring and potential adjustment of the ciclosporin dose, as described in regulatory documents.
• CYP3A4 Substrates: UDCA is formally documented to induce the CYP3A4 enzyme. This metabolic induction can lead to a reduced exposure (lower AUC/Cmax) for co-administered substrates, including nitrendipine and dapsone.

Efficacy Counteraction

The therapeutic efficacy of Dexo is documented to be reduced when co-administered with oestrogenic hormones or high doses of progestins. These substances are known to increase cholesterol secretion into the bile, which directly counteracts the cholelitholytic (gallstone dissolving) goal of treatment, making their concurrent use restricted during this specific therapy.

Modulating Bile Composition and Solubilizing Cholesterol

This mechanistic domain centers on the competitive displacement of toxic, hydrophobic bile acids and the inhibition of cholesterol secretion from the liver into the bile. This action profoundly alters the bile's chemistry, making it unsaturated with cholesterol and creating a physicochemical environment that favors cholesterol solubilization.

---

️ Stabilizing Cellular Membranes and Inhibiting Apoptosis

The drug involves a cytoprotective mechanism by directly stabilizing the mitochondrial membrane within liver and bile duct cells. This stabilization inhibits the MPT Pore and blocks the downstream molecular cascades that trigger programmed cell death (apoptosis), thereby contributing to the cell's structural stability following chemical exposure.

---

Regulating Bile Flow and Transport Kinetics

This mechanism involves the modulation of specific membrane-bound transport proteins (like AE2) and nuclear receptors (like FXR) to stimulate the active secretion of water and bicarbonate. This regulation leads to a choleretic effect—an increase in bile flow and volume—which affects bile flow and volume and influences the regulatory dynamics of the hepatobiliary system.

How to Use Dexo

This section describes the administration and dosing principles for Dexo (Ursodeoxycholic Acid/UDCA).

---

Administration and Dosage Rules

The approved route of administration for Dexo is oral, with the medicine available in solid forms like capsules and tablets, or as an oral suspension.

Feature	Official Administration Guideline
Dose Calculation	Dosing is typically weight-based, ranging from 8 to 16 mg per kilogram (mg/kg) of body weight daily, depending on the specific treated condition.
Timing & Food	The medicine is generally taken with food, particularly when the daily amount is administered in divided doses.
Form Handling	Capsules and tablets must be swallowed whole with water and should not be crushed or chewed to ensure correct delivery.

---

Frequency and Duration Patterns

Treatment frequency is structured to ensure consistent bile concentrations. For chronic conditions like Primary Biliary Cholangitis (PBC), the total daily dose is initially administered in two to four divided doses. After a period of initial treatment, the total daily dose may be consolidated and taken once daily in the evening.

For PBC, the official use protocol is intended as a long-term plan and may be continued indefinitely. Conversely, for gallstone dissolution, the treatment is time-bound, typically lasting for six months up to two years, and must be continued for at least three months after the stones have dissolved.

Special Population Note: Specific, weight-based dosing regimens are detailed for pediatric patients with certain cholestatic liver disorders.

Dexo: Recent Clinical Evidence

Dexo was studied for Primary Biliary Cholangitis (PBC), a long-term condition marked by functional limitations and systemic imbalance. Studies that have explored this use include Randomized Controlled Trials (RCTs), as well as very large-scale, long-term observational studies and patient registries in adults. Researchers tracked changes in key biochemical markers of liver health, such as alkaline phosphatase and total bilirubin, as outcomes reflecting systemic or functional imbalance.

The findings related to critical long-term outcomes, such as occurrences of a liver transplant or all-cause mortality, are largely drawn from large, multicenter patient registries. These larger datasets describe patterns observed in the studies that include a slower rate of disease progression and less frequent occurrences of liver transplantation in observed populations, which was associated with receiving the study drug in registry settings. The early RCTs often included modest sample sizes and limited follow-up durations to assess these late-stage events.

Dexo was also evaluated in research settings for individuals with cholesterol gallstones. Research examined the ability of the study drug to achieve dissolution, verified by imaging. Findings related to dissolution varied across studies, with dissolution observed in a significant portion of patients who met strict criteria (small, radiolucent stones). However, research consistently describes a pattern of stone recurrence after the intervention was completed.

Studies exploring how symptoms change over time evaluated Dexo for managing intense itching (pruritus). Some trials described patterns suggesting the study drug was associated with patterns of change in the severity of pruritus and corresponding changes in bile acid levels. However, findings across different research scenarios have not been uniform, and the certainty regarding the long-term observation of symptom relief remains low.

Key Studies & References Long-Term Effects of Mid-Dose Ursodeoxycholic Acid in Primary Biliary Cirrhosis (Meta-analysis including extended follow-up data on survival and liver transplantation)

Common questions about Dexo (FAQ)

Q: Is Dexo considered a strong or high-potency corticosteroid?

According to official regulatory documents, Dexo contains Ursodeoxycholic Acid (UDCA), which is classified as a cholelitholytic and hepatoprotective agent—a type of naturally occurring bile acid. It is not classified as a corticosteroid, which is the class of medicines that includes drugs like prednisone.

---

Q: Does Dexo start working immediately, or does it take a few days to feel the full effect?

The time it takes for the drug concentration in the body to reach a consistent level, known as a steady-state, is approximately 3 weeks of repeated dosing. This indicates that consistent bile levels are established over time, and the full therapeutic benefit may be observed gradually over several weeks.

---

Q: How long does the anti-inflammatory effect of a single dose of Dexo typically last?

Pharmacokinetic data from studies show that after treatment is stopped, the drug’s concentration in the body gradually decreases. It typically declines to a low level (approximately 5% to 10% of its steady-state) about 1 week after the last dose.

---

Q: Is it normal to feel more energetic or restless after taking Dexo?

While feeling more energetic is not commonly listed in official adverse reaction data, insomnia (difficulty sleeping) has been reported in clinical trials. If persistent changes in energy or rest occur, these can be reviewed with a healthcare professional.

---

Q: Why does Dexo sometimes cause trouble sleeping (insomnia)?

Insomnia, or trouble sleeping, is listed as a less common adverse reaction reported in clinical trials. It is important to note that the occurrence and severity of this side effect can vary among individuals.

---

Q: What are the signs of fluid retention (edema) linked to Dexo use?

Although generally not common, some official safety documents report swelling, known as edema, as an adverse reaction. This may include reports of swelling (edema) in areas such as the hands, ankles, feet, or lower legs.

---

Q: Can taking Dexo for a short period still cause side effects like 'moon face'?

The side effect known as 'moon face' is primarily associated with corticosteroids. Since Dexo is a bile acid and not a corticosteroid, this specific side effect is not reported in its official drug labeling.

---

Q: Can Dexo be used in children, and are there special concerns for pediatric patients?

Dexo is approved for use in children aged 6 years and older for certain liver disorders, such as cystic fibrosis related liver disease. However, its effectiveness for treating gallstones is not established in children under 6 years of age.

---

Q: Is Dexo safe for use during pregnancy, or should it be avoided?

Official information states that the medicine is generally not recommended for use during the first trimester of pregnancy. For women of child-bearing potential, official product information indicates the use of effective non-hormonal contraception is needed during treatment for gallstone dissolution.

---

Q: What does it mean that Dexo can cause 'adrenal gland suppression'?

Adrenal gland suppression is primarily associated with corticosteroid medications. Since Dexo is a bile acid, not a corticosteroid, this condition is not listed as an adverse reaction in the official drug labeling.

---

Q: Does Dexo interact with birth control pills or affect hormone levels?

The therapeutic effect of Dexo for dissolving gallstones may be reduced if it is taken with oestrogenic hormones or high doses of progestins. This is because these hormones can counteract the drug's goal of dissolving the gallstones.

---

Q: Why do some people experience muscle weakness or pain while taking Dexo?

Muscle weakness or pain are not listed as common side effects. However, official safety documents have reported arthralgia (joint pain/stiffness) and arthritis as adverse reactions during clinical trials for gallstone dissolution.

---

Q: Is there any research on Dexo's effectiveness for migraines or chronic pain?

The medicine is officially indicated only for specific liver disorders, such as Primary Biliary Cholangitis, and for the dissolution of certain cholesterol gallstones. Migraines or chronic pain are not listed as approved indications in regulatory documents.

---

Q: Does Dexo cause temporary hair growth or hair loss as a side effect?

Hair loss, known as alopecia, is classified as a 'Not Known' adverse reaction based on postmarketing surveillance. This means it has been reported by users but is not well characterized by frequency.

---

Q: Is it a common concern that Dexo can affect fertility or reproductive health?

Animal studies have not shown that the drug affects fertility. However, official safety documents state that human data regarding the specific effect of treatment on fertility is currently missing.

---

Q: What is the meaning of 'moon face' and why does it occur with some Dexo users?

The term 'moon face' describes the facial swelling that is a recognized side effect of corticosteroid medications. Since Dexo is a bile acid and not a corticosteroid, this specific side effect is not reported in its official drug labeling.

---

Q: What are some real-world examples of inflammatory conditions that Dexo treats?

The approved uses for the drug include treating Primary Biliary Cholangitis (a chronic liver disorder) and dissolving certain types of cholesterol gallstones. It is indicated for conditions that involve bile composition abnormalities and liver cell protection.

---

Q: Is there a known 'maximum' time someone can safely take Dexo continuously?

For the treatment of Primary Biliary Cholangitis (PBC), the official protocol is intended as a long-term plan and may be continued indefinitely. For the dissolution of gallstones, however, treatment is time-bound and typically lasts for six months up to two years.

Storage and Disposal Requirements for Dexo (Ursodeoxycholic Acid)

Official Storage Conditions

Dexo must be stored at a temperature below 25°C and protected from both direct sunlight and moisture, consistent with regulatory standards for product stability. The medicine must be kept in its original, tightly closed container; tablets or capsules should not be transferred to other packaging.

Special attention is required for stability: segments of scored tablets, if used, remain viable for only 28 days when kept in the original bottle. The medicine must always be stored out of the sight and reach of children.

Disposal Instructions

To manage pharmaceutical waste, Dexo should not be thrown away with household waste or disposed of via wastewater. Unused or expired medicine must be taken to a pharmacy or an authorized drug take-back program for safe disposal, as specified by official waste management guidelines.